NanoViricides Tallies Investment Total by a Director, Milton Boniuk, MD
Sep 20, 2013 (Close-Up Media via COMTEX) --
NanoViricides, Inc. reported that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company has invested a total of $7 Million in the Company during the 2013 calendar year.
According to a release, Dr. Boniuk was the single largest investor with $3 Million in the recently concluded registered direct offering. Previously, he had invested $4 Million in the Company's convertible debenture financing concluded in February. Professor Boniuk has also invested in the Company in earlier rounds of financing. He made these investments both personally as well as from his charitable foundation and other interests. Professor Boniuk joined the Company's Board as an independent director in May, at the request of the Company's executives. He says that his confidence in the Company has only continued to grow as he sees the Company's management and execution now from a closer perspective.
When asked why he has made these investments, he explained that "As I became familiar with the technology and the various on-going programs that the Company has, it became apparent that the potential was nothing short of amazing. Dr. Diwan explained to me how it would be possible to create a novel drug against a previously unknown virus in a matter of weeks. The NanoViricides team has demonstrated this capability by creating potential drug candidates for the MERS human Coronavirus in just a few weeks. I was impressed by the business acumen of the senior management as demonstrated by their ability to bring in six commercially important drug candidates in the Company's pipeline, in a relatively short time frame. I was also impressed by their receiving orphan drug designation for the dengue/dengue hemorrhagic fever drug candidate, the interest shown by the British Government Agency in a collaboration on MERS and H7N9, as well as the progress they've made in the construction of the new R&D and cGMP pilot production facility. Although I have known Dr. Seymour professionally for many years, I was introduced to the Company by my sister, Vivien Boniuk, MD, also an ophthalmologist, who had performed the animal studies on the Company's drug candidates for adenovirus and herpes virus infections of the eye."
The Company further reported that Dr. Vivien Boniuk was the very first investor in the Company, and has continued to be a major investor all along.
NanoViricides is developing broad-spectrum anti-influenza drugs as part of a drug pipeline.
((Comments on this story may be sent to email@example.com))
[ InfoTech Spotlight's Homepage ]